ArticleCureus2025
Comparative Effectiveness of Sodium-Glucose Co-transporter 2 Inhibitors and Thiazolidinediones in Reducing Adverse Cardiovascular Events in Type 2 Diabetes.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Cardiovascular disease is the leading cause of morbidity and mortality among patients with type 2 diabetes mellitus (T2DM). While both sodium-glucose co-transporter 2 inhibitors (SGLT-2is) and thiazolidinediones (TZDs) have demonstrated cardiovascular effects, comparative data in real-world South Asian populations remain limited. Objective This study aimed to compare the effectiveness of SGLT-2is and TZDs in reducing adverse cardiovascular events (ACVEs) in patients with T2DM. Methodology A prospective, comparative cohort study was conducted at HITEC Institute of Medical Sciences, Taxila, from January to December 2024. A total of 240 T2DM patients with high cardiovascular risk were recruited and divided equally into two groups: one receiving SGLT-2is (dapagliflozin or empagliflozin) and the other receiving TZDs (pioglitazone). Baseline clinical and biochemical parameters were recorded and followed for 12 months. Outcomes included changes in blood pressure, body mass index (BMI), glycemic and lipid profiles, renal function, and incidence of major adverse cardiovascular events (MACE). Results At baseline, both groups were comparable in age (mean 56.4±9.8 years), sex distribution (58% male), and hypertension duration (8.6±5.1 years). After 12 months, the SGLT-2is group showed greater reductions in systolic blood pressure (130.5±9.1 mmHg vs. 134.7±10.2 mmHg; p<0.05), BMI (28.7±3.4 vs. 29.9±3.6 kg/m²), and HbA1c (7.1±0.7% vs. 7.4±0.8%). Lipid profiles and fasting glucose also improved more in the SGLT-2is group. The incidence of MACE was significantly lower in the SGLT-2is group (8.3%) compared to the TZD group (21.7%), with fewer cardiovascular deaths, myocardial infarctions, strokes, and heart failure hospitalizations. Conclusion SGLT-2is demonstrated superior cardiometabolic outcomes and a lower risk of ACVEs compared to TZDs, supporting their preferential use in patients with T2DM at elevated cardiovascular risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.